1801547-16-9

PROTAC RIPK degraders -2 is a non-peptide PROTAC based on von Hippel-Lindau and targets serine-threonine kinase RIPK2, which is highly selective to the degradation of RIPK2. PROTAC RIPK degrader-2 acts as an activator to increase cell death and activate ion channels in cancer cells. PROTAC RIPK degrader-2 also can inhibit protein interactions, such as receptors and ligands, involved in a variety of diseases, such as cancer and diabetes[1][2].

RIPK2; VHL

[1] Bondeson DP, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015 Aug;11(8):611-7. DOI:10.1038/nchembio.1858
[2] Wang C, et al. VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. Eur J Med Chem. 2022 Jan 5;227:113906. DOI:10.1016/j.ejmech.2021.113906